NCT01410331View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Critical Limb Ischemia
Interventions
BIOLOGICAL

JVS-100(4 mg) or placebo/8 injections

4 mg of JVS-100 or placebo delivered in 8 injections

BIOLOGICAL

JVS-100(8 mg) or placebo/8 injections

8 mg of JVS-100 or placebo delivered in 8 injections

BIOLOGICAL

JVS-100(8 mg) or placebo/16 injections

8 mg of JVS-100 or placebo delivered in 16 injections

BIOLOGICAL

JVS-100(16 mg) or placebo/16 injections

16 mg of JVS-100 or placebo delivered in 16 injections

Trial Locations (7)

10467

Montefiore Medical Center, The Bronx

35211

Cardiology PC, Birmingham

44304

Summa Health System, Akron

55407

Minneapolis Heart Institute Foundation, Minneapolis

60611

Northwestern Memorial Hospital/Northwestern University, Chicago

110060

Sir Ganga Ram Hospital, New Delhi

122001

Medanta-The Medicity, Haryāna

Sponsors
All Listed Sponsors
lead

Juventas Therapeutics, Inc.

INDUSTRY